It's a complex organization. If you look at the organization chart, There's the personnel side, which includes an investigation division and a research division, which I spoke about. The investigation division is responsible for reviewing the prices of medicines. When the investigation division concludes that the price of a patented medicine may be excessive, the pharmaceutical company is advised, and it can challenge the determination. In the event of a challenge, there may be a hearing, which would be attended by two members of the board, appointed by the Governor in Council.
So that's one of the roles of the members. As Mr. Davies mentioned earlier in exchanges with the minister, another role of the members is to work on developing guidelines and to handle the consultation process, as provided in section 96 of the Patent Act. That applies only to the members.